ATNX Athenex Inc

Price (delayed)

$0.5

Market cap

$55.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.81

Enterprise value

$148.68M

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment ...

Highlights
Athenex's debt has decreased by 15% YoY and by 15% from the previous quarter
The quick ratio has plunged by 76% YoY but it has grown by 9% from the previous quarter
ATNX's net income is down by 27% year-on-year but it is up by 3.8% since the previous quarter
ATNX's equity has dropped by 76% year-on-year and by 26% since the previous quarter
The gross profit has dropped by 58% year-on-year and by 48% since the previous quarter

Key stats

What are the main financial stats of ATNX
Market
Shares outstanding
111.83M
Market cap
$55.92M
Enterprise value
$148.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.45
Price to sales (P/S)
0.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.37
Earnings
Revenue
$108.88M
EBIT
-$182.51M
EBITDA
-$178.23M
Free cash flow
-$137.62M
Per share
EPS
-$1.81
Free cash flow per share
-$1.25
Book value per share
$0.34
Revenue per share
$0.99
TBVPS
$1.5
Balance sheet
Total assets
$236.86M
Total liabilities
$216.06M
Debt
$133.74M
Equity
$37.99M
Working capital
$50.8M
Liquidity
Debt to equity
3.52
Current ratio
1.63
Quick ratio
1
Net debt/EBITDA
-0.52
Margins
EBITDA margin
-163.7%
Gross margin
18%
Net margin
-176.5%
Operating margin
-171.1%
Efficiency
Return on assets
-59.2%
Return on equity
-180.3%
Return on invested capital
-81.9%
Return on capital employed
-116.9%
Return on sales
-167.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNX stock price

How has the Athenex stock price performed over time
Intraday
-7.41%
1 week
2.44%
1 month
-0.1%
1 year
-90.06%
YTD
-63.24%
QTD
-39.72%

Financial performance

How have Athenex's revenue and profit performed over time
Revenue
$108.88M
Gross profit
$19.58M
Operating income
-$186.32M
Net income
-$192.14M
Gross margin
18%
Net margin
-176.5%
The operating margin has dropped by 92% year-on-year and by 12% since the previous quarter
Athenex's net margin has plunged by 61% YoY and by 6% from the previous quarter
The gross profit has dropped by 58% year-on-year and by 48% since the previous quarter
The operating income has plunged by 51% YoY

Growth

What is Athenex's growth rate over time

Valuation

What is Athenex stock price valuation
P/E
N/A
P/B
1.45
P/S
0.51
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.37
The EPS has grown by 6% from the previous quarter but it has contracted by 2.8% YoY
ATNX's equity has dropped by 76% year-on-year and by 26% since the previous quarter
The P/B is 75% lower than the 5-year quarterly average of 5.9 and 42% lower than the last 4 quarters average of 2.5
The stock's P/S is 96% below its 5-year quarterly average of 11.5 and 77% below its last 4 quarters average of 2.2
The revenue has decreased by 21% YoY and by 9% from the previous quarter

Efficiency

How efficient is Athenex business performance
Athenex's return on equity has shrunk by 109% YoY and by 23% QoQ
ATNX's return on invested capital has dropped by 71% year-on-year and by 14% since the previous quarter
The ROS has plunged by 71% YoY and by 6% from the previous quarter
ATNX's ROA is down by 41% YoY and by 4.6% QoQ

Dividends

What is ATNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNX.

Financial health

How did Athenex financials performed over time
The total assets is 10% more than the total liabilities
The quick ratio has plunged by 76% YoY but it has grown by 9% from the previous quarter
Athenex's current ratio has shrunk by 68% YoY but it has increased by 17% QoQ
ATNX's equity has dropped by 76% year-on-year and by 26% since the previous quarter
Athenex's debt has decreased by 15% YoY and by 15% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.